Onyx announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) submission for carfilzomib, a next generation proteasome inhibitor, for the potential treatment of patients with relapsed and refractory multiple myeloma. The drug candidate was developed by Proteolix which in licensed the initial discovery from academic researchers at Yale and Cal Tech.
CDD’s Barry Bunin was on one of the early patents to help translate the discovery from academia to industry: Smyth, M. S.; Laidig, G. J; Borchardt, R. T.; Bunin, B. A.; Crews, C. M.; Musser, J. H.; Schneekloth, J. S.; Chabala, J. C. Compounds for Enzyme Inhibition. Patent No. US 2005/0245434 A1; issued 3 Nov 2005 (Proteolix, Inc).
For the full announcement, see the Onyx Pharmaceuticals website: http://www.onyx-pharm.com/news/onyx-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-carfilzomib-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma
This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities!
CDD Vault: Drug Discovery Informatics your whole project team will embrace!
Translated with Google Translate